 |
|
 |
- July 4, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Diabetes: The Magnitude of the problem and it's relationship to the Metabolic Syndrome"Prof. Bernard Zinman (biography)
English - 2003-06-16 - 14 minutes
|
 | (11 slides) |
Summary :
The prevalence of diabetes is expected to increase by 76% by 2025, and this increase seems to be taking place not only in Europe and North America, but in developing countries as well. Driving this epidemic is another one - the obesity epidemic, and we know that larger and larger food portions have been contributing to this. Regarding pathophysiology, we know that beta cell failure leads to type 2 diabetes, but more and more we're focusing on the role of adipocytes in insulin resistance, specifically how the "adipokines" contribute to this condition. We know that using TZDs to change insulin resistance improves so many associated factors such as hyperinsulinemia, ambulatory BP, dyslipidemia, visceral fat, microalbuminuria and hyperglycemia, and what remains to be seen is whether the TZDs can actually also change CVD outcomes. The ADOPT Study is now telling us about the prevalence of metabolic syndrome in recently diagnosed type 2 diabetic patients, and the usefulness of NCEP criteria in identifying these patients, which will be talked about here.
Learning objectives :
The participant will be given a recap of the recent foci of research on the pathophysiology of type 2 diabetes, as well as an introduction to baseline findings from the ADOPT study addressing the prevalence of the metabolic syndrome in recently diagnosed type 2 diabetics:
- Beta cell failure leads to type 2 diabetes, but treatment of insulin resistance improves many of its associated factors such as hyperinsulinemia, ambulatory BP, dyslipidemia, visceral fat, microalbuminuria and hyperglycemia, with data still to come on whether CVD outcomes can also be changed.
- New research is giving us more and more information on the role of “adipokines” in contributing to insulin resistance.
- The ADOPT Study has so far revealed a > 80% prevalence of metabolic syndrome in recently-diagnosed type 2 diabetics, and points to NCEP criteria as being superior to WHO criteria in identifying affected patients.
Bibliographic references :
Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1737-43.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
